Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study].
Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Desjardins A, Xuan KH, Chauffert B. Guiu S, et al. Among authors: desjardins a. Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):588-94. doi: 10.1016/j.neurol.2008.04.003. Epub 2008 Jun 3. Rev Neurol (Paris). 2008. PMID: 18565358 French.
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Vredenburgh JJ, et al. Among authors: desjardins a. Clin Cancer Res. 2007 Feb 15;13(4):1253-9. doi: 10.1158/1078-0432.CCR-06-2309. Clin Cancer Res. 2007. PMID: 17317837 Clinical Trial.
Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
Desjardins A, Reardon DA, Herndon JE 2nd, Marcello J, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Bailey L, Bigner DD, Friedman AH, Friedman HS, Vredenburgh JJ. Desjardins A, et al. Clin Cancer Res. 2008 Nov 1;14(21):7068-73. doi: 10.1158/1078-0432.CCR-08-0260. Clin Cancer Res. 2008. PMID: 18981004 Free PMC article. Clinical Trial.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS. Vredenburgh JJ, et al. Among authors: desjardins a. J Clin Oncol. 2007 Oct 20;25(30):4722-9. doi: 10.1200/JCO.2007.12.2440. J Clin Oncol. 2007. PMID: 17947719 Clinical Trial.
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS. Reardon DA, et al. Among authors: desjardins a. Cancer. 2011 Dec 1;117(23):5351-8. doi: 10.1002/cncr.26188. Epub 2011 May 16. Cancer. 2011. PMID: 21590689 Free PMC article. Clinical Trial.
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.
Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS. Reardon DA, et al. Among authors: desjardins a. J Neurooncol. 2012 Mar;107(1):155-64. doi: 10.1007/s11060-011-0722-2. Epub 2011 Oct 11. J Neurooncol. 2012. PMID: 21986722 Free PMC article. Clinical Trial.
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.
Sathornsumetee S, Cao Y, Marcello JE, Herndon JE 2nd, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN. Sathornsumetee S, et al. Among authors: desjardins a. J Clin Oncol. 2008 Jan 10;26(2):271-8. doi: 10.1200/JCO.2007.13.3652. J Clin Oncol. 2008. PMID: 18182667 Free PMC article. Clinical Trial.
Experience with irinotecan for the treatment of malignant glioma.
Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Vredenburgh JJ, et al. Among authors: desjardins a. Neuro Oncol. 2009 Feb;11(1):80-91. doi: 10.1215/15228517-2008-075. Epub 2008 Sep 10. Neuro Oncol. 2009. PMID: 18784279 Free PMC article. Review.
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP. Cuneo KC, et al. Among authors: desjardins a. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24. doi: 10.1016/j.ijrobp.2010.12.074. Epub 2011 Apr 12. Int J Radiat Oncol Biol Phys. 2012. PMID: 21489708 Free PMC article.
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
Reardon DA, Vredenburgh JJ, Coan A, Desjardins A, Peters KB, Gururangan S, Sathornsumetee S, Rich JN, Herndon JE, Friedman HS. Reardon DA, et al. Among authors: desjardins a. J Neurooncol. 2011 Dec;105(3):621-7. doi: 10.1007/s11060-011-0631-4. Epub 2011 Jul 9. J Neurooncol. 2011. PMID: 21744079 Free PMC article. Clinical Trial.
382 results